Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lentivirus-mediated gene therapy for Fabry disease.
Khan A, Barber DL, Huang J, Rupar CA, Rip JW, Auray-Blais C, Boutin M, O'Hoski P, Gargulak K, McKillop WM, Fraser G, Wasim S, LeMoine K, Jelinski S, Chaudhry A, Prokopishyn N, Morel CF, Couban S, Duggan PR, Fowler DH, Keating A, West ML, Foley R, Medin JA. Khan A, et al. Among authors: duggan pr. Nat Commun. 2021 Feb 25;12(1):1178. doi: 10.1038/s41467-021-21371-5. Nat Commun. 2021. PMID: 33633114 Free PMC article. Clinical Trial.
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS. Russell JA, et al. Biol Blood Marrow Transplant. 2002;8(9):468-76. doi: 10.1053/bbmt.2002.v8.pm12374451. Biol Blood Marrow Transplant. 2002. PMID: 12374451 Free article. Clinical Trial.
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities.
Daly A, Savoie ML, Geddes M, Chaudhry A, Stewart D, Duggan P, Bahlis N, Storek J, Brown C, Shafey M, Turner AR, Russell J. Daly A, et al. Biol Blood Marrow Transplant. 2012 Dec;18(12):1921-6. doi: 10.1016/j.bbmt.2012.07.017. Epub 2012 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 22842330 Free article.
Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Murray K, Culham M, Luider J, Fourie T, Rashid-Kolvear F, Bahlis NJ. Jimenez-Zepeda VH, et al. Leuk Lymphoma. 2016;57(4):973-6. doi: 10.3109/10428194.2015.1085534. Epub 2015 Oct 8. Leuk Lymphoma. 2016. PMID: 26450458 No abstract available.
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
Ousia S, Kalra A, Williamson TS, Prokopishyn N, Dharmani-Khan P, Khan FM, Jimenez-Zepeda V, Jamani K, Duggan PR, Daly A, Russell JA, Storek J. Ousia S, et al. Among authors: duggan pr. Clin Transplant. 2020 Sep;34(9):e14018. doi: 10.1111/ctr.14018. Epub 2020 Jul 4. Clin Transplant. 2020. PMID: 32573834
73 results